Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Hernexeos, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option – Boehringer

Written by | 31 Mar 2026

The FDA approved Boehringer Ingelheim’s Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase… read more.

Hernexeos (zongertinib tablets) approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC – Boehringer

Written by | 17 Sep 2025

Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved as monotherapy by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable, locally advanced or… read more.

FDA grants accelerated approval to Hernexeos as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC – Boehringer

Written by | 15 Aug 2025

Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved by the FDA. The kinase inhibitor is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.